Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Befovacimab in Hemophilia A or B
NCT03597022Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of befovacimab in hemophilia A, hemophilia B (HB), sponsored by Bayer. Started Jul 2018; status: terminated.
02
Drugs
befovacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03597022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597022.